• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Metabolism
Tag:

Metabolism

Health

Scientists Discover a Surprising Reason Intermittent Fasting Extends Life

by Chief Editor April 26, 2026
written by Chief Editor

The Fresh Science of Longevity: It’s Not Just About the Fast

For years, the conversation around intermittent fasting has centered on the “fast” itself—the hours spent abstaining from food to trigger weight loss and cellular cleanup. However, groundbreaking research from UT Southwestern Medical Center is shifting the narrative. The secret to a longer, healthier life may not lie in the deprivation, but in the recovery.

View this post on Instagram about Nature Communications, Nature
From Instagram — related to Nature Communications, Nature

New findings published in Nature Communications suggest that the health-promoting effects of calorie restriction are heavily dependent on the refeeding phase. This is the critical window where the body recalibrates its metabolic machinery as it transitions from a fasted state back to a fed state.

Did you realize? To uncover these metabolic secrets, researchers studied Caenorhabditis elegans—a type of roundworm commonly used in labs. They found that short fasting cycles could extend the lifespan of these organisms by over 60%.

The “Refeeding” Secret: Why the Break Matters

The biological magic happens through a process called metabolic switching. During a fast, cells exhaust their glucose supplies and switch to breaking down stored lipids (fats) for energy. This process, known as catabolism, is managed by a specific protein called NHR-49.

The "Refeeding" Secret: Why the Break Matters
The Role Protein When Peter Douglas

The Role of the NHR-49 Protein

When glucose levels drop, NHR-49 activates to trigger the breakdown of fats. But the real key to longevity is what happens when you eat again. Normally, NHR-49 is switched off once food is available, allowing the body to stop burning fat and start restoring energy reserves.

In a fascinating experiment, researchers led by Peter Douglas, Ph.D., and Lexus Tatge, Ph.D., discovered that if NHR-49 remains active even after feeding resumes, the lifespan-extending benefits of fasting completely disappear. This proves that the ability to properly “shut down” the fasting metabolism is what actually drives the longevity benefits.

Pro Tip: The research highlights that metabolic flexibility—the ability of your body to switch efficiently between burning carbs and fats—is a primary marker of health and aging.

Future Trends: Beyond Strict Dietary Regimens

The discovery of the KIN-19 enzyme, which modifies NHR-49 through phosphorylation to turn it off, opens the door to a new era of medicine. We are moving toward a future where the benefits of intermittent fasting could be achieved without the need for strict, often difficult, dietary restrictions.

Future Trends: Beyond Strict Dietary Regimens
Nature Communications Nature Communications

From Dieting to Molecular Targeting

If scientists can target the metabolic switch directly, they may be able to mimic the effects of fasting pharmacologically. By adjusting how the body handles the transition between fasted and fed states, it may be possible to trigger the longevity pathways that usually require hours of hunger.

This shift represents a move toward preventive medicine. Instead of treating isolated age-related diseases, the focus is shifting toward targeting aging itself—the single greatest risk factor for human disease—to enhance the overall quality of life.

For more on how to implement these patterns safely, you can explore our comprehensive guide to fasting patterns or read the full study via Nature Communications.

Frequently Asked Questions

What is the refeeding phase?

The refeeding phase is the period immediately following a fast when food is reintroduced and the body adjusts its metabolism from burning stored fats back to using incoming nutrients.

How does NHR-49 affect lifespan?

NHR-49 controls the breakdown of lipids during fasting. However, for longevity benefits to occur, NHR-49 must be deactivated during the refeeding phase to allow the body to restore energy reserves.

Can we receive fasting benefits without actually fasting?

While current evidence is based on laboratory studies in roundworms, researchers believe that targeting the metabolic switches (like NHR-49 and KIN-19) could eventually allow humans to gain longevity benefits without strict dieting.

What is metabolic switching?

Metabolic switching is the body’s ability to shift its energy source from glucose (sugar) to lipids (fats) during periods of calorie restriction and then back again upon refeeding.

Join the Conversation: Do you practice intermittent fasting, or do you find strict diets too difficult to maintain? Let us know your experience in the comments below, or subscribe to our newsletter for the latest breakthroughs in longevity science!

April 26, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Researchers uncover new mechanism linking metabolism, immunity, and skeletal health

by Chief Editor April 25, 2026
written by Chief Editor

Rethinking the “Heavy Bone” Myth: The Hidden Cost of Obesity

For years, a common belief in skeletal biology was that higher body weight actually benefited bone health. The logic was simple: increased mechanical loading from extra weight should, in theory, strengthen the skeleton. However, groundbreaking research is now flipping this narrative on its head.

We now realize that obesity doesn’t just put physical pressure on joints; it fundamentally reshapes the internal environment of the bone marrow. This shift transforms the marrow from a supportive niche into a driver of bone degradation, challenging everything we thought we knew about the relationship between weight and skeletal integrity.

Did you know? Bone marrow adipose tissue (BMAT) is not just passive fat storage. It is an active endocrine organ that can secrete signaling molecules to regulate both your immune system and your bone density.

The Biological Trigger: How Bone Marrow Fat Destroys Bone

The mechanism behind this bone loss is a complex chain reaction. In obese conditions, bone marrow adipocytes (fat cells) expand rapidly. These expanded cells increase the production of a signaling molecule called MCP-1.

View this post on Instagram about Bone, Future
From Instagram — related to Bone, Future

MCP-1 acts as a beacon, recruiting myeloid immune cells and steering them toward an immunosuppressive state. These cells begin expressing PD-L1 (programmed death-ligand 1). Even as these PD-L1+ cells suppress T-cell activity—potentially explaining why obesity is linked to reduced vaccine effectiveness and higher infection risks—they do something far more damaging to the skeleton.

These PD-L1-expressing cells interact with PD-1 receptors on osteoclast precursors. This specific interaction promotes the differentiation of these precursors into mature osteoclasts—the specialized cells responsible for resorbing and degrading mineralized bone matrix. The result is a significant loss of both trabecular and cortical bone volume.

For more on how metabolic health affects the body, witness our guide on metabolic health and systemic inflammation.

Future Therapeutic Trends: Repurposing Cancer Drugs for Bone Health

One of the most exciting prospects arising from this research is the potential to repurpose existing medical technology. The PD-1/PD-L1 axis is already a primary target in cancer immunotherapy. This suggests a future where immune checkpoint inhibitors could be adapted to treat obesity-related bone disorders.

Targeting the JNK Pathway

Recent data indicates that PD-1/PD-L1 inhibitors can exert direct effects on bone metabolism. By inhibiting the JNK pathway, these agents may reduce the proliferation and resorptive capacity of osteoclasts, effectively slowing down bone loss.

Pharmacological Blockade

Research has shown that blocking the PD-1/PD-L1 signaling axis during the early stages of osteoclast precursor development can mitigate bone resorption. This opens the door for targeted pharmacological interventions that preserve bone integrity without needing to address total body weight first.

Pharmacological Blockade
Bone Future Health
Pro Tip: Future treatment for obesity-related osteoporosis may require a multidisciplinary approach, combining the expertise of endocrinologists, immunologists, and bone specialists to manage the intersection of metabolism and immunity.

The Broader Impact: Immunity and Skeletal Health

The discovery of this link suggests that the skeleton is far more integrated with the immune system than previously realized. The expansion of bone marrow fat creates an “immunosuppressive microenvironment” that disrupts the delicate immune equilibrium.

This suggests that treating bone loss in obese patients isn’t just about calcium or vitamin D; it’s about managing the immune checkpoint pathways. By reducing bone marrow adipogenesis—as seen in studies using BMAd-Pparg KO models—researchers have successfully reduced the number of PD-L1+ myeloid cells and improved bone structure.

Check out our related article on how immune checkpoints regulate the body to learn more about PD-L1.

Frequently Asked Questions

What is the role of MCP-1 in bone loss?

MCP-1 is a chemokine secreted by expanded bone marrow fat in obese individuals. It recruits myeloid immune cells and promotes their expression of PD-L1, which eventually drives the formation of bone-resorbing osteoclasts.

Frequently Asked Questions
Bone Future

Can PD-1/PD-L1 inhibitors actually help bones?

Yes, evidence suggests that blocking this pathway can reduce osteoclast proliferation and resorptive activity, potentially protecting bone volume in the context of obesity.

Why does obesity lead to weaker bones if weight usually strengthens them?

While mechanical loading is beneficial, the metabolic changes caused by obesity—specifically the expansion of bone marrow fat—trigger an immune response that accelerates bone resorption, outweighing the benefits of the extra weight.

Does bone marrow fat affect the rest of the immune system?

Yes. The PD-L1+ myeloid cells recruited by bone marrow fat suppress T-cell activity, which may contribute to impaired immune responses, such as decreased vaccine effectiveness.

Join the Conversation

Do you think immune-based therapies will turn into the new standard for treating osteoporosis? Let us know your thoughts in the comments below or subscribe to our newsletter for the latest breakthroughs in metabolic medicine!

April 25, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Scientists identify new inflammatory mechanism to treat chronic health conditions

by Chief Editor April 24, 2026
written by Chief Editor

The Shift Toward Precision Inflammation Control

For decades, the medical community has viewed inducible nitric oxide synthase (iNOS) primarily as a factory for nitric oxide. The prevailing assumption was that this protein drove inflammation through the chemicals it produced. However, groundbreaking research published in Nature Metabolism has revealed a hidden side to iNOS: it acts as a physical switch that can shut down the body’s natural anti-inflammatory mechanisms.

View this post on Instagram about The Shift Toward Precision Inflammation Control For, Nature Metabolism
From Instagram — related to The Shift Toward Precision Inflammation Control For, Nature Metabolism

This discovery changes the game for how we approach chronic inflammation. Rather than simply trying to dampen the immune response across the board—which can depart patients vulnerable to infections—the focus is shifting toward “precision handles.” By targeting the physical interaction between proteins, scientists may soon be able to unlock the body’s own brakes on inflammation without disabling the rest of the immune system.

Did you know?

The protein IRG1 produces a metabolite called itaconate, which serves as a biological “brake” to stop the inflammatory response from running too hard for too long. When iNOS binds to IRG1, it effectively cuts the brake lines.

Moving Beyond Nitric Oxide

The most significant trend emerging from this research is the move away from targeting protein products and toward targeting protein shapes. Researchers from the University of Surrey and the University of Oxford found that the physical shape of iNOS—stabilized by a cofactor called tetrahydrobiopterin (BH4)—is what allows it to bind to IRG1 inside the mitochondria.

Crucially, this interaction happens regardless of whether iNOS is actually producing nitric oxide. Which means that future therapies could potentially disrupt the iNOS-IRG1 bond to restore itaconate production, allowing the body to naturally resolve inflammation in conditions like arthritis and Crohn’s disease.

New Horizons for Cardiovascular and Autoimmune Treatment

The implications of this molecular switch extend far beyond a single protein. Given that chronic inflammation is a common thread in various systemic diseases, this discovery points toward a unified strategy for treating several high-impact conditions.

Scientists discover mechanism of action and an actionable inflammatory axis for air pollution in…

The IBD-Heart Connection

There is a documented link between Inflammatory Bowel Disease (IBD), including Crohn’s disease, and cardiovascular disease (CVD). Research indicates that gut dysbiosis and systemic inflammation can increase cardiovascular risk, with metabolic remodeling playing a key role in atherosclerosis and heart failure.

By targeting the iNOS-IRG1 interface, clinicians may find a way to treat the systemic inflammation that fuels both gastrointestinal distress and vascular damage. This integrated approach could reduce the morbidity associated with the overlap of IBD and CVD.

Pro Tip for Patients:

When discussing inflammatory conditions with your healthcare provider, ask about the link between systemic inflammation and cardiovascular health. Managing one often requires a holistic view of the other.

Targeting Mitochondrial Energy Management

Another emerging trend is the focus on how immune cells manage energy. The research shows that when iNOS is absent, IRG1 associates with different proteins involved in glycolysis and cell metabolism. This suggests that iNOS doesn’t just block the “brake” (itaconate); it similarly sequesters IRG1 away from other vital metabolic roles.

Future treatments may focus on “metabolic reprogramming,” adjusting how immune cells use energy to prevent the tissue damage that underlies many chronic diseases. This approach is being funded by organizations like the British Heart Foundation to find more precise ways to intervene in heart health.

Frequently Asked Questions

What is iNOS and why does it matter?
Inducible nitric oxide synthase (iNOS) is a protein that produces nitric oxide during inflammation. While essential for fighting infection, its ability to bind to IRG1 can prevent the body from stopping the inflammatory response, leading to chronic tissue damage.

Frequently Asked Questions
Crohn Subscribe

Which diseases could this discovery help treat?
This research opens new routes for treating cardiovascular disease, arthritis, Crohn’s disease, and other inflammatory conditions.

How is this different from current inflammation treatments?
Most current treatments target the substances proteins produce. This new approach targets the physical interaction (the “interface”) between proteins, offering a more precise way to control the immune response.

What role does the mitochondria play in this process?
The interaction between iNOS and IRG1 occurs inside the mitochondria. By disrupting this bond, the protein IRG1 is freed to produce itaconate, which helps modulate the immune response.

Stay Ahead of Medical Breakthroughs

Want to dive deeper into the latest research on precision medicine and inflammatory health? Subscribe to our newsletter or leave a comment below to let us know which medical breakthroughs you want us to cover next!

Subscribe Now

April 24, 2026 0 comments
0 FacebookTwitterPinterestEmail
Tech

Targeting glutamine metabolism enhances CAR-macrophage cancer therapy

by Chief Editor April 21, 2026
written by Chief Editor

The New Frontier of Immunotherapy: Fueling the Fight Against Solid Tumors

For years, the promise of CAR-T cell therapy has transformed the treatment of blood cancers. Still, solid tumors have remained a stubborn fortress, protected by a hostile tumor microenvironment (TME) that effectively starves and exhausts immune cells. The latest breakthrough in metabolic engineering is shifting the conversation from how we target cancer to how we fuel the cells fighting it.

Recent research led by Sun Yat-sen University, published in Cancer Biology & Medicine, has pinpointed a critical metabolic vulnerability in tumor-associated macrophages (TAMs). These cells, which should be hunting cancer, often suffer from significant metabolic dysregulation—specifically a failure to utilize glutamine, a nutrient essential for their antitumor functions.

Did you know? Tumor-associated macrophages (TAMs) often lose their ability to fight cancer not because they lack the “instructions” to attack, but because they lack the metabolic “fuel” to execute the mission.

Beyond Targeting: The Rise of Metabolic Engineering

The traditional approach to CAR-macrophage (CAR-M) therapy focuses on the receptor—ensuring the macrophage can recognize a specific protein on the tumor, such as HER2. Whereas essential, Here’s only half the battle. If the macrophage enters the TME and finds itself in a “nutrient desert,” its effectiveness plummets.

View this post on Instagram about Metabolic, Beyond Targeting
From Instagram — related to Metabolic, Beyond Targeting

The game-changing strategy involves the overexpression of SLC38A2, a key glutamine transporter. By engineering CAR-Ms to overexpress this transporter, researchers have successfully reprogrammed how these cells utilize glutamine. This isn’t just a minor tweak; It’s a fundamental restoration of “glutamine fitness.”

Measurable Impacts on Macrophage Function

When CAR-macrophages are metabolically enhanced via SLC38A2, the functional upgrades are significant:

  • Enhanced Phagocytosis: There is a marked increase in the ability of CAR-Ms to engulf and destroy HER2+ tumor cells.
  • Increased Activation: These cells show higher expression of costimulatory molecules, specifically CD80 and CD86.
  • Cytokine Surge: The production of pro-inflammatory cytokines, such as TNF-α, is amplified, creating a more aggressive antitumor environment.
  • Mitochondrial Shifts: Metabolic reprogramming leads to increased mitochondrial fragmentation, a sign of enhanced macrophage activation.

For more on how these mechanisms work, you can explore the full study via Cancer Biology & Medicine.

Future Trends: Scaling Metabolic Fitness Across Cancers

The success of SLC38A2 engineering in HER2+ breast cancer models suggests a broader blueprint for treating various solid tumors. We are likely moving toward a future where “metabolic profiling” is a standard part of immunotherapy design.

1. Expanding the Target List

While this research focused on HER2+ tumors, the principle of restoring glutamine uptake is likely applicable to other solid tumors where TAMs are suppressed. Future iterations of CAR-M therapy will likely combine specific antigen targeting with a suite of metabolic boosters tailored to the specific nutrient deficiencies of different tumor types.

1. Expanding the Target List
Metabolic Solid Future

2. The Dual-Benefit Effect: Activating T-Cells

One of the most exciting prospects is the “ripple effect” of metabolic engineering. Dr. Qiyi Zhao noted that enhancing macrophage function doesn’t just aid the macrophages themselves; it supports broader immune responses, including the activation of CD8+ T-cells. This suggests a future where CAR-Ms act as “metabolic anchors,” preparing the TME for other immune cells to enter and attack more effectively.

Pro Tip for Researchers: When designing next-generation CAR-M therapies, look beyond the CAR construct. Integrating single-cell transcriptomic and metabolomic profiling can reveal hidden metabolic vulnerabilities in the TME that, if corrected, could exponentially increase therapeutic efficacy.

3. Overcoming the Immunosuppressive Barrier

Solid tumors are notorious for their immunosuppressive environments. By reprogramming glutamine utilization, researchers are finding a way to make immune cells persistent. The trend is moving toward creating “hardened” immune cells that can thrive in conditions that would typically shut them down.

Targeting Glutamine Metabolism in M2-Tumor Associated Macrophages… – Raekwon Williams (Grade 12)

Frequently Asked Questions

What is SLC38A2?

SLC38A2 is a glutamine transporter. In the context of cancer immunotherapy, overexpressing this transporter helps CAR-macrophages take up more glutamine, restoring their ability to fight tumors.

How do CAR-macrophages differ from CAR-T cells?

While both use chimeric antigen receptors to target cancer, CAR-macrophages (CAR-Ms) utilize phagocytosis (engulfing cells) and the secretion of pro-inflammatory cytokines to destroy tumors and activate other immune cells.

How do CAR-macrophages differ from CAR-T cells?
Metabolic Solid Cancer

Why is glutamine important for fighting cancer?

Glutamine is a critical nutrient for immune cell metabolism. When its utilization is impaired—as is often the case in the tumor microenvironment—macrophages lose their antitumor functionality.

Can this be used for all types of cancer?

The current research focused on HER2+ breast cancer, but the study suggests that targeting metabolic pathways like glutamine utilization could be a promising strategy for a wide range of solid tumors.

What are your thoughts on the shift toward metabolic engineering in cancer treatment? Could this be the key to finally cracking solid tumors? Let us know in the comments below or subscribe to our newsletter for the latest updates in immunotherapy.

April 21, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Eating oranges daily may shift lipid patterns in fatty liver disease

by Chief Editor April 20, 2026
written by Chief Editor

Beyond the Plate: The Future of Fighting Fatty Liver with Precision Nutrition

For decades, the medical advice for fatty liver disease was simple, if frustrating: “lose weight and eat better.” But as we move deeper into the era of personalized medicine, we are discovering that the fight against Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is far more nuanced than a simple calorie deficit.

Recent research, including trials on the impact of specific citrus varieties like “Navelina” oranges, suggests that we are on the cusp of a shift. We are moving away from generic dietary guidelines and toward lipidomics—the high-definition mapping of fats in our blood to tailor nutrition to the individual.

Did you know? MASLD (formerly known as NAFLD) is now recognized not just as a liver issue, but as a systemic metabolic condition. This name change reflects a growing understanding that the liver is often the “canary in the coal mine” for overall metabolic health.

The Rise of Lipidomics: Seeing the Full Picture

Traditionally, doctors looked at a “lipid panel”—total cholesterol, LDL, and HDL. While useful, this is like looking at a forest from a satellite; you see the green, but you miss the individual trees.

Lipidomics changes the game. It allows scientists to identify hundreds of specific lipid species. As seen in recent clinical trials, we can now track how specific nutrients shift the ratio of pro-inflammatory fatty acids (like arachidonic acid) to anti-inflammatory ones (like eicosapentaenoic acid or EPA).

The future trend here is clear: biomarker-driven dieting. Instead of a one-size-fits-all Mediterranean diet, patients may soon receive a “lipid fingerprint” analysis that tells them exactly which polyphenols or omega-3 sources their specific liver needs to reduce inflammation.

Nutraceuticals: Food as Targeted Therapy

We are seeing a transition from “healthy eating” to “nutraceutical intervention.” The study on Navelina oranges is a prime example. While the results were modest, the direction of the change—a shift toward an anti-inflammatory profile—points to the power of polyphenols.

Polyphenols are bioactive compounds found in plants that act as signaling molecules in the body. In the context of MASLD, these compounds may help “switch off” the pathways that lead to hepatic steatosis (fat accumulation in the liver).

Why Specificity Matters

Not all oranges are created equal. The focus on the “Navelina” variety highlights a growing trend in agricultural precision. Future trends will likely involve “functional foods” bred or selected for higher concentrations of specific metabolites that target liver enzymes or insulin sensitivity.

Pro Tip: If you’re looking to support your liver health today, focus on “whole-food” polyphenols. Instead of supplements, reach for deep-colored berries, extra virgin olive oil, and citrus fruits. The synergy of fibers and vitamins in whole foods often enhances the absorption of these liver-protecting compounds.

The Gut-Liver Axis: The Next Frontier

One of the most exciting trends in metabolic research is the “Gut-Liver Axis.” We now know that the liver is intimately connected to the gut microbiome via the portal vein.

View this post on Instagram about Liver, Metabolic
From Instagram — related to Liver, Metabolic

When we consume polyphenol-rich foods, they aren’t just digested; they are metabolized by gut bacteria into smaller, more potent molecules. These metabolites then travel directly to the liver, where they can reduce oxidative stress and improve lipid metabolism.

Expect to see a surge in synbiotic diets—combinations of prebiotics (like the fibers in oranges) and probiotics—specifically designed to prime the gut to produce the metabolites the liver needs to heal. For more on this, explore our comprehensive guide to the microbiome.

AI and the Hyper-Personalized Diet

The most significant leap will be the integration of Artificial Intelligence. Imagine an app that syncs your continuous glucose monitor (CGM), your latest lipidomics report, and your genetic predispositions to suggest a daily menu.

For a patient with MASLD, AI might suggest a specific dose of citrus-derived polyphenols on days when inflammatory markers are high, or increase MUFA (monounsaturated fatty acid) intake when LDL patterns shift. This moves us from “preventative” health to “predictive” health.

According to data from global health organizations, metabolic syndrome is rising globally. The scalability of AI-driven nutrition may be the only way to manage this crisis at a population level.

Frequently Asked Questions

Can eating oranges actually cure fatty liver?
While oranges contain beneficial polyphenols that may improve lipid profiles and reduce inflammation, they are not a “cure.” They work best as part of a broader lifestyle intervention including weight management and exercise.

10 Surprising Health Benefits of Eating Oranges Daily

What is the difference between NAFLD and MASLD?
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) is the updated term. It removes the word “alcoholic” (which was seen as stigmatizing) and emphasizes the metabolic drivers of the disease, such as obesity and type 2 diabetes.

What are the best fats for liver health?
Focus on MUFAs (found in olive oil and avocados) and n-3 PUFAs (found in fatty fish and walnuts). These are generally associated with lower liver inflammation compared to saturated trans fats.

Join the Conversation on Metabolic Health

Are you incorporating functional foods into your diet to support your liver? Or are you curious about how lipidomics could change your healthcare? Let us know in the comments below or subscribe to our newsletter for the latest breakthroughs in precision nutrition!

Subscribe for Updates

April 20, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Fat-producing enzyme identified as key driver of damage in Parkinson’s disease

by Chief Editor April 9, 2026
written by Chief Editor

Parkinson’s Disease: A New Target in Fat Metabolism?

A newly identified enzyme, glycerol-3-phosphate acyltransferase (GPAT), is emerging as a potential key player in the progression of Parkinson’s disease. Research from Nanyang Technological University, Singapore (NTU Singapore) suggests that GPAT’s role in fat production within brain cells could amplify the damage caused by the protein α-synuclein, a hallmark of the disease.

The Link Between Fat Metabolism and Parkinson’s

For years, Parkinson’s disease has been primarily associated with the loss of dopamine-producing neurons in the brain. However, recent studies are highlighting the importance of metabolic processes, particularly fat metabolism, in the disease’s development. Scientists at NTU LKCMedicine discovered that GPAT alters how brain cells process fats, exacerbating the effects of α-synuclein accumulation.

How GPAT Impacts Brain Cells

Brain cells rely on mitochondria – often called “power stations” – to generate energy. The study revealed that GPAT contributes to damage within these mitochondria, reducing their energy production capacity. Simultaneously, GPAT increases the toxicity of α-synuclein. This “double hit” significantly impairs brain cell function and survival.

Pro Tip: Understanding the intricate relationship between cellular energy production and protein accumulation is crucial for developing effective therapies for neurodegenerative diseases like Parkinson’s.

Experimental Evidence: From Fruit Flies to Mouse Cells

Researchers utilized fruit flies engineered to produce excess human α-synuclein, a common model for studying Parkinson’s. Reducing GPAT activity in these flies led to less brain cell damage and improved movement. Similar protective effects were observed in mouse brain cells grown in the lab.

FSG67: A Potential Therapeutic Avenue

The team tested FSG67, a compound known to block GPAT activity, previously studied for obesity and metabolic disorders. Treatment with FSG67 reduced the harmful effects of α-synuclein, including protein clumping and fat damage, in both fruit flies and mouse brain cells. This suggests that inhibiting GPAT could be a viable therapeutic strategy.

The Growing Need for New Treatments

Parkinson’s disease affects over 11 million people worldwide, and the number is expected to rise, particularly in countries with aging populations like Singapore, where approximately three in every 1,000 individuals over 50 suffer from the disease. Currently, there is no cure, emphasizing the urgent need for innovative treatment approaches.

Expert Commentary

Professor Tan Eng King, from the National Neuroscience Institute, commented that the study provides “novel insights into the interplay between metabolic dysregulation and brain dysfunction,” suggesting that targeting metabolic pathways could be a relevant strategy for brain disorders. He as well highlighted the importance of understanding the molecular events underlying the disease’s progression to develop effective therapies.

Future Trends and Research Directions

The identification of GPAT as a key driver of damage in Parkinson’s disease opens several exciting avenues for future research. Scientists will likely focus on:

  • Developing GPAT inhibitors: Creating new drugs specifically designed to block GPAT activity and mitigate its harmful effects.
  • Investigating metabolic biomarkers: Identifying biomarkers related to fat metabolism that could aid diagnose Parkinson’s disease earlier and track disease progression.
  • Personalized medicine approaches: Tailoring treatments based on an individual’s metabolic profile and genetic predisposition to Parkinson’s.
  • Exploring the role of diet: Investigating how dietary interventions can influence fat metabolism in the brain and potentially gradual down disease progression.

FAQ

  • What is GPAT? Glycerol-3-phosphate acyltransferase is an enzyme involved in the production of fats within brain cells.
  • How does GPAT relate to Parkinson’s disease? Research suggests GPAT amplifies the damage caused by α-synuclein, a protein that accumulates in the brains of people with Parkinson’s.
  • Is there a cure for Parkinson’s disease? Currently, there is no cure for Parkinson’s disease, but research is ongoing to develop new treatments.
  • What is FSG67? FSG67 is a compound that blocks the activity of GPAT and has shown protective effects in laboratory studies.

This research represents a significant step forward in understanding the complex mechanisms underlying Parkinson’s disease. By targeting fat metabolism, scientists may be able to develop new and effective therapies to combat this debilitating condition.

Want to learn more about neurological disorders? Explore our other articles on brain health and neurodegenerative diseases here.

April 9, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Do multi-strain probiotics improve long covid symptoms?

by Chief Editor March 27, 2026
written by Chief Editor

Can Probiotics Offer a Path to Long COVID Relief? Emerging Research Explores Gut-Brain Connection

The lingering effects of COVID-19, often referred to as long COVID, continue to challenge medical science. While research expands, a growing body of evidence suggests a surprising potential ally in the fight against persistent symptoms: probiotics. New studies are focusing on the gut microbiome and its intricate relationship with the immune system, inflammation and even cognitive function in individuals experiencing long COVID.

The Gut-COVID Connection: Why the Microbiome Matters

The gut microbiome – the trillions of bacteria, fungi, and other microorganisms residing in our digestive tract – plays a crucial role in overall health. It influences immune responses, nutrient absorption, and even mental wellbeing. Emerging research indicates that SARS-CoV-2 infection can disrupt this delicate balance, leading to gut dysbiosis, a state of microbial imbalance. This disruption is thought to contribute to the wide range of symptoms associated with long COVID.

Inflammation, a hallmark of both acute COVID-19 and its long-term effects, is closely linked to gut health. A compromised microbiome can exacerbate inflammation, potentially fueling the persistent symptoms experienced by many long COVID sufferers. Modulating the gut microbiome through interventions like probiotics is therefore being explored as a potential therapeutic strategy.

Recent Findings: Modest Shifts, Promising Signals

A recent study published in Microorganisms investigated the impact of a multi-strain probiotic intervention on individuals with long COVID. Researchers found that the probiotic blend – containing Saccharomyces boulardii, Lacticaseibacillus rhamnosus GG, and two Lactiplantibacillus plantarum strains – induced selective changes in the gut microbiome. Specifically, certain beneficial bacterial genera, like Adlercreutzia and Ruminococcaceae, increased in abundance, while potentially harmful bacteria, such as Prevotella_9, decreased.

While these changes weren’t dramatic, they were statistically significant in some cases and aligned with patterns observed in individuals recovering from acute COVID-19. Functional prediction analysis suggested the probiotics might improve bacterial energy metabolism and reduce oxidative stress. Trends toward reduced inflammation and improved liver biomarkers were also observed, though these were not statistically significant.

Beyond Lactobacillus and Bifidobacterium: The Rise of Multi-Strain Approaches

Traditionally, probiotics featuring Lactobacillus and Bifidobacterium have been the focus of gut health research. However, the latest studies suggest that a broader approach, incorporating strains like Saccharomyces boulardii, may be more effective in addressing the complex challenges of long COVID. S. Boulardii is known for its anti-inflammatory and gut-protective properties, offering a complementary mechanism of action.

Synbiotics and the Future of Long COVID Treatment

The concept of “synbiotics” – combining probiotics with prebiotics (fibers that feed beneficial bacteria) – is gaining traction as a potentially more powerful approach to restoring gut health. Research published in The Lancet suggests that synbiotics could offer a new treatment framework for post-acute COVID-19 syndrome. By providing both the beneficial bacteria and the fuel they need to thrive, synbiotics may offer a more sustainable and effective solution.

Fatigue, Memory Loss, and the Microbiome: Emerging Evidence

Some of the most debilitating symptoms of long COVID include fatigue and cognitive dysfunction, often referred to as “brain fog.” Interestingly, recent studies indicate a link between gut health and these neurological symptoms. Probiotics have shown promise in reducing fatigue and improving memory in some long COVID patients, potentially by modulating the gut-brain axis – the bidirectional communication pathway between the gut microbiome and the central nervous system.

Pro Tip:

Don’t self-treat. Always consult with a healthcare professional before starting any new supplement regimen, especially if you have underlying health conditions.

Challenges and Future Directions

Despite the promising findings, research on probiotics and long COVID is still in its early stages. Many studies are limited by small sample sizes, non-randomized designs, and the use of functional prediction analysis rather than direct measurement of microbial activity. Larger, well-controlled clinical trials are needed to confirm these initial findings and determine the optimal probiotic strains, dosages, and treatment durations.

personalized approaches may be crucial. The gut microbiome is highly individual, and the most effective probiotic intervention may vary depending on a person’s specific microbial profile and symptom presentation.

FAQ: Probiotics and Long COVID

  • Can probiotics cure long COVID? No, probiotics are not a cure for long COVID, but they may help manage some symptoms.
  • Which probiotic strains are best for long COVID? Multi-strain probiotics containing Saccharomyces boulardii, Lacticaseibacillus rhamnosus GG, and Lactiplantibacillus plantarum strains show promise.
  • How long does it take to see results? The timeframe for seeing results can vary, but studies typically involve a 12-week intervention period.
  • Are there any side effects of taking probiotics? Probiotics are generally safe for most people, but some may experience mild digestive discomfort.

Did you know? The gut microbiome is as unique as a fingerprint, varying significantly from person to person.

The exploration of probiotics as a potential therapeutic strategy for long COVID represents a fascinating intersection of gut health, immunology, and neurology. While more research is needed, the emerging evidence suggests that nurturing the gut microbiome may offer a valuable tool in the ongoing effort to alleviate the burden of this complex and challenging condition.

Want to learn more about gut health and its impact on overall wellbeing? Explore our other articles on microbiome research and the gut-brain connection.

March 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Breast reduction surgery is linked to lower diabetes and heart risk

by Chief Editor March 24, 2026
written by Chief Editor

Beyond Aesthetics: Could Breast Reduction Be a Metabolic Game Changer?

For decades, breast reduction surgery has been recognized for its ability to alleviate physical discomfort and improve quality of life. But emerging research suggests this procedure may offer benefits that extend far beyond the cosmetic – potentially impacting long-term metabolic health. A recent study analyzing data from over 23,000 women indicates a link between breast reduction and a reduced risk of conditions like type 2 diabetes and hypertension.

The Unexpected Connection: Macromastia and Metabolic Risk

Traditionally, breast reduction surgery has addressed issues like chronic back, neck, and shoulder pain, skin irritation, and limitations in physical activity. Patients often report significant improvements in self-esteem and body image following the procedure. Though, the potential for systemic metabolic effects is a relatively new area of investigation. Previous research on fat removal procedures, such as liposuction, has hinted at metabolic improvements, but the impact of breast tissue reduction remained less clear.

Study Highlights: Lower Risks Across the Board

The study, currently available on the SSRN preprint server, categorized patients by body mass index (BMI) to assess the impact of surgery. Researchers found that women who underwent breast reduction experienced notable reductions in several metabolic risk factors. Specifically, in the BMI 25-30 group, surgery was associated with lower rates of diabetes, low HDL cholesterol, elevated blood pressure, and metabolic syndrome. Similar benefits were observed in the BMI 30-35 group, though the reduction in diabetes risk wasn’t statistically significant in this cohort.

Interestingly, the benefits appeared most pronounced in normal-weight and overweight patients. This suggests that the metabolic impact of breast reduction may be influenced by a patient’s baseline weight and overall health status.

How Might This Perform? Unpacking the Potential Mechanisms

Even as the study establishes an association, it doesn’t definitively prove causation. Several theories attempt to explain the observed metabolic benefits. Reducing the weight of breast tissue could alleviate chronic inflammation, a known contributor to insulin resistance and cardiovascular disease. Improved physical activity levels post-surgery may play a role in enhancing metabolic function. The removal of hormonally active breast tissue is another potential factor, though further research is needed to explore this connection.

Diabetes and Heart Health: A Closer Look at the Data

The study revealed that after accounting for various factors, women who had breast reduction surgery had a lower prevalence of type 2 diabetes, hypertension, and disorders of lipoprotein metabolism compared to those who did not. For example, in the BMI 30-35 group, the prevalence of hypertension was 12.36% in the surgery group versus 4.94% in the control group before propensity score matching. These findings align with recent research linking breast reduction surgery to lower diabetes and heart risk.

Important Considerations and Future Research

Researchers acknowledge that residual confounding and differences in healthcare access could contribute to the observed associations. The study also excluded patients with a history of breast cancer or those who had undergone other body contouring procedures, limiting the generalizability of the findings. Further research, including randomized controlled trials, is needed to confirm these results and elucidate the underlying mechanisms.

Did you understand? The American Society of Plastic Surgeons guidelines already emphasize the need for more evidence regarding glycemic control in patients with diabetes undergoing breast reduction surgery.

FAQ

Q: Does breast reduction surgery guarantee I won’t develop diabetes or heart disease?
A: No, it doesn’t guarantee prevention, but the study suggests it may lower your risk.

Q: Is this benefit seen in all patients?
A: The benefits appear more pronounced in normal-weight and overweight individuals.

Q: What further research is needed?
A: Randomized controlled trials are needed to confirm these findings and understand the mechanisms involved.

Pro Tip: Discuss your individual risk factors and potential benefits with a qualified healthcare professional before considering breast reduction surgery.

Want to learn more about the impact of surgery on overall health? Explore our articles on metabolic syndrome and the link between inflammation and chronic disease.

Have questions about breast reduction surgery or its potential health benefits? Share your thoughts in the comments below!

March 24, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Menopause may raise women’s Alzheimer risk earlier than doctors once thought

by Chief Editor March 19, 2026
written by Chief Editor

Alzheimer’s Prevention: Why Midlife is a Critical Window for Women

A growing body of research suggests that the midlife transition, particularly menopause, represents a pivotal period for Alzheimer’s disease (AD) prevention in women. Traditionally, increased longevity was considered the primary reason women are disproportionately affected by AD – comprising nearly two-thirds of all cases. However, a recent review published in The Journal of Clinical Investigation challenges this view, highlighting female-specific biological factors and the potential for targeted interventions.

The Female Brain: Unique Vulnerabilities

The hormonal shifts accompanying menopause aren’t simply a natural part of aging; they can fundamentally alter brain biology and metabolism. Declining estrogen levels, coupled with rising follicle-stimulating hormone (FSH) and luteinizing hormone (LH), may contribute to the buildup of amyloid plaques and tau tangles – hallmark characteristics of AD. Brain imaging studies demonstrate that postmenopausal women often exhibit greater amyloid-beta deposition, reduced cerebral glucose metabolism, and decreased gray matter volume compared to premenopausal women and men.

Pro Tip: Recognizing that AD may begin decades before symptoms appear emphasizes the importance of proactive brain health strategies starting in midlife.

Reproductive Health as a Risk Indicator

Several reproductive health factors are emerging as potential indicators of AD risk. Early menopause (before age 45), premenopausal bilateral oophorectomy (removal of both ovaries), and a shorter reproductive span – the time between menarche (first menstrual period) and menopause – are all linked to increased risk. These factors reduce overall exposure to estrogen, which plays a protective role in the brain by reducing inflammation and supporting neuronal survival.

Interestingly, parity (number of childbirths) appears to have a complex relationship with AD risk. Some studies suggest that having one to four children may be protective, while having five or more may increase risk, though findings remain mixed.

Subjective Cognitive Decline: An Early Warning Sign?

Many women experience memory lapses, difficulty concentrating, or mental fog during perimenopause. This subjective cognitive decline (SCD) is often dismissed as a normal part of aging, but research suggests it may signal the onset of cognitive impairment. Brain scans of women experiencing SCD reveal less structural integrity in brain areas affected by AD, decreased functional connectivity, and reduced energy production in brain cells.

Hormone Therapy: A Complex Equation

Menopause hormone therapy (MHT), including estrogen therapy (ET) or combined estrogen-progestogen therapy (EPT), has been extensively studied for its potential to prevent AD. Initial trials, like the Women’s Health Initiative Memory Study (WHIMS), indicated an increased risk of dementia with MHT initiation in older adults (aged 65-79). However, newer evidence suggests that timing is crucial.

The “timing hypothesis” proposes that MHT initiated near menopause may actually reduce AD risk by 11% to 30%. This protective effect is thought to be greatest when therapy is started within 10 years of menopause. Current guidelines do not recommend MHT for general AD prevention, but estrogen therapy may be considered for women experiencing early menopause, particularly after oophorectomy.

Beyond Hormones: Lifestyle and Health Disparities

Genetic factors, such as the apolipoprotein E epsilon 4 (APOE ε4) allele, similarly play a role in AD risk, potentially exerting a greater influence in women than in men. Lifestyle factors – cardiovascular health, physical inactivity, and poor sleep – grow more prevalent after menopause and are strongly associated with cognitive impairment. Health disparities exist, with Black and Hispanic women experiencing more menopausal symptoms and a higher rate of dementia, potentially due to a combination of biological and socioenvironmental factors.

The Future of AD Prevention: Precision and Biomarkers

Advances in biomarkers – including blood-based biomarkers (BBBs), cerebrospinal fluid (CSF) analysis, and positron emission tomography (PET) imaging – are enabling earlier detection of AD pathology, even years before symptoms appear. This opens the door to personalized prevention strategies tailored to individual risk factors, genetic profiles, and hormonal status.

The current approach to AD prevention often aggregates data by sex, potentially underestimating the cumulative risk burden in women. A shift towards sex-specific prevention frameworks is crucial.

Frequently Asked Questions

Q: Is menopause a direct cause of Alzheimer’s disease?
A: Menopause isn’t a direct cause, but the hormonal changes associated with it can significantly influence brain health and potentially increase vulnerability to AD.

Q: When is the best time to start hormone therapy for AD prevention?
A: The timing hypothesis suggests that hormone therapy may be most beneficial when initiated near menopause, ideally within 10 years of the final menstrual period.

Q: What lifestyle changes can I make to reduce my AD risk?
A: Maintaining cardiovascular health, engaging in regular physical activity, prioritizing sleep, and managing stress are all important lifestyle factors for brain health.

Q: Are there any latest biomarkers for early AD detection?
A: Yes, blood-based biomarkers (BBBs) are showing promise for detecting AD pathology years before symptoms appear.

Want to learn more about women’s brain health? Explore the Weill Cornell Women’s Brain Initiative.

Share your thoughts and experiences in the comments below! What steps are you taking to prioritize your brain health?

March 19, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Gut-derived blood markers may help predict who develops coronary heart disease

by Chief Editor March 19, 2026
written by Chief Editor

Your Gut Could Hold the Key to Predicting – and Preventing – Heart Disease

For decades, heart disease has remained the leading cause of death globally. But what if a significant piece of the puzzle wasn’t in the heart itself, but in the bustling ecosystem within our gut? Emerging research is increasingly pointing to a strong connection between the trillions of microbes residing in our digestive system and our cardiovascular health. A recent multi-cohort study, published in PLOS Medicine, has identified several gut microbiota-related metabolites in the bloodstream that are linked to the later development of coronary heart disease (CHD).

The Gut-Heart Axis: A Newly Defined Connection

The concept of a “gut-heart axis” isn’t entirely new, but the level of detail now emerging is groundbreaking. Researchers have long known that the gut microbiota generates numerous metabolites – substances not naturally produced by the human body – that enter the bloodstream and influence overall health. This latest study, evaluating data from over 896 individuals across Asian, Black, and White populations, provides compelling evidence that specific microbial metabolites can be associated with an increased risk of CHD.

Uncovering the Key Players: Metabolites and CHD Risk

The study identified 73 significant metabolites initially, narrowing down to nine that were consistently linked to CHD after rigorous validation. These include imidazole propionate, 3-hydroxy-2-ethylpropionate, 4-hydroxyphenylacetate, trans-4-hydroxyproline, 3-hydroxybutyrate, trimethylamine N-oxide, phenylacetyl-L-glutamine, 4-hydroxyhippuric acid, and indolepropionate. These metabolites are involved in pathways related to amino acids, carbohydrates, and energy metabolism.

Interestingly, the strength of these associations varied across different populations, suggesting that genetics, diet, and lifestyle factors all play a role in how gut microbes influence heart health. Some associations were similarly partially explained by metabolic conditions, indicating that these metabolites may contribute to CHD risk through complex interactions.

Beyond Observation: The Future of Gut-Targeted Therapies

While this study is observational – meaning it can’t definitively prove cause and effect – it opens up exciting possibilities for future research and potential therapeutic interventions. The identification of these specific metabolites provides new biomarker targets for predicting CHD risk. Imagine a future where a simple blood test could assess your gut microbial profile and identify individuals at higher risk, allowing for early intervention.

Personalized Nutrition and the Microbiome

One promising avenue is personalized nutrition. Diet has a profound impact on the composition of the gut microbiome. Understanding how specific foods influence the production of these key metabolites could lead to dietary recommendations tailored to an individual’s gut profile, aiming to reduce their CHD risk. For example, increasing fiber intake can promote the growth of beneficial bacteria that produce short-chain fatty acids, known to have protective effects on the heart.

Probiotics, Prebiotics, and Fecal Microbiota Transplantation

Researchers are also exploring the potential of probiotics (live microorganisms) and prebiotics (substances that feed beneficial bacteria) to modulate the gut microbiome and improve cardiovascular health. While more research is needed, early studies suggest that certain probiotic strains may assist lower blood pressure and cholesterol levels. In more extreme cases, fecal microbiota transplantation – transferring gut bacteria from a healthy donor to a recipient – is being investigated as a potential treatment for various conditions, though its application to CHD is still in its early stages.

Challenges and Considerations

Despite the exciting progress, several challenges remain. The observational nature of the current study means that it’s difficult to determine whether the metabolites are a cause or a consequence of CHD. Further research, including randomized controlled trials, is needed to establish causality. The complexity of the gut microbiome and the individual variability in microbial composition pose significant hurdles to developing universally effective gut-targeted therapies.

Did you know?

The gut microbiome contains trillions of microorganisms, outnumbering human cells by a factor of 10 to 1!

FAQ: Gut Health and Heart Disease

  • What is the gut-heart axis? It refers to the bidirectional communication between the gut microbiome and the cardiovascular system.
  • Can diet really impact my heart health through my gut? Yes, diet significantly influences the composition of your gut microbiome, which in turn affects the production of metabolites that can impact heart health.
  • Are probiotics a guaranteed solution for heart disease? Not necessarily. While some strains show promise, more research is needed to determine which probiotics are most effective and for whom.
  • What are metabolites? These are substances produced by the gut microbiome that enter the bloodstream and can influence various bodily functions.

The link between gut health and heart disease is becoming increasingly clear. While more research is needed, the identification of key microbial metabolites offers a new and promising avenue for preventing and treating this leading cause of mortality. By understanding the complex interplay between our gut microbes and our cardiovascular system, we can pave the way for a healthier future.

Want to learn more about the latest advancements in heart health? Explore our other articles on preventative cardiology and innovative treatments. Don’t forget to subscribe to our newsletter for regular updates!

March 19, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Ukraine Summons Israeli Ambassador Over Stolen Grain in Haifa

    April 28, 2026
  • This Utah congressman wants to get AI out of children’s toys

    April 28, 2026
  • Napier brothers’ Hokey Pokey LA ice cream shops a hit with Lenny Kravitz, Sandra Bullock, Leonardo DiCaprio

    April 28, 2026
  • 吉田直樹揭秘FF14:曾考慮單機版與8.0原名絕對零度

    April 28, 2026
  • Paul Pierce Blasts Kevin Durant’s Rockets Leadership

    April 28, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World